All In MedTech

Device Trial Radar · NCT00348205

A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia

Last checked: Nov 20, 2026Latest source record: Sep 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Jun 2005

Primary completion

Jan 2009

Study completion Mar 2009

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedNot on our public-company list
Sponsor type
Industry
First posted
Jul 4, 2006

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to demonstrate the safety and effectiveness of wavefront laser refractive surgery treatments for hyperopia and astigmatism.

Conditions

  • Hyperopia
  • Astigmatism

Interventions

  • Technolas 217z Zyoptix LaserDevice

    Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better at 12 Months and 24 MonthsTime frame: 24 months
  2. Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of Emmetropia.Time frame: 12 months
  3. The Percentage of Eyes With a Postoperative Subjective Manifest Refraction Spherical Equivalent (MRSE) Within ± 1.00 Diopter (D) and ± 0.50 D of EmmetropiaTime frame: 24 months

3 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bausch & Lomb

    Rochester, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.